Effect of the artesunate mefloquine fixed dose combination in the malaria transmission in Amazon basin communities.
Abstract
This presentation describes a study of the use of the new fixed-dose antimalarial combination ASMQ (artesunate + mefloquine) in Acre state in the Amazon region of Brazil. There was a significant reduction in the number of malaria cases, the ratio of Plasmodium falciparum cases to P. vivax cases, and the recurrence rate; there were no reports of serious adverse effects and only one non-serious adverse event. It is concluded, subject to the limitations of the study, that the trial was successful.
Citation
Presentation from ‘The ASMQ Fixed-Dose Combination to treat Malaria: From Blueprint to Use in the Field’. Symposium from American Society of Tropical Medicine and Hygiene 58th Annual Meeting, Washington, DC, USA, 19 November 2009.
Links
Updates to this page
Published 1 January 2009